nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—VDAC1—Mitochondrial protein import—TIMM10—muscle cancer	0.227	0.542	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—DMD—muscle cancer	0.0475	0.114	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—DMD—muscle cancer	0.0404	0.0965	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Muscle contraction—CALD1—muscle cancer	0.0381	0.091	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Muscle contraction—DMD—muscle cancer	0.0319	0.0763	CbGpPWpGaD
Dihydroxyaluminium—VDAC2—renal system—muscle cancer	0.0309	0.0691	CbGeAlD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—TIMM10—muscle cancer	0.0289	0.0691	CbGpPWpGaD
Dihydroxyaluminium—VDAC3—smooth muscle tissue—muscle cancer	0.0267	0.0598	CbGeAlD
Dihydroxyaluminium—VDAC3—renal system—muscle cancer	0.0257	0.0576	CbGeAlD
Dihydroxyaluminium—VDAC1—smooth muscle tissue—muscle cancer	0.0254	0.0569	CbGeAlD
Dihydroxyaluminium—VDAC1—renal system—muscle cancer	0.0245	0.0547	CbGeAlD
Dihydroxyaluminium—VDAC3—cardiac atrium—muscle cancer	0.0231	0.0515	CbGeAlD
Dihydroxyaluminium—VDAC1—cardiac atrium—muscle cancer	0.0219	0.049	CbGeAlD
Dihydroxyaluminium—VDAC2—head—muscle cancer	0.0207	0.0462	CbGeAlD
Dihydroxyaluminium—VDAC3—tendon—muscle cancer	0.0201	0.0449	CbGeAlD
Dihydroxyaluminium—VDAC2—testis—muscle cancer	0.02	0.0447	CbGeAlD
Dihydroxyaluminium—VDAC3—bone marrow—muscle cancer	0.0195	0.0435	CbGeAlD
Dihydroxyaluminium—VDAC1—tendon—muscle cancer	0.0191	0.0427	CbGeAlD
Dihydroxyaluminium—TNNC1—cardiac atrium—muscle cancer	0.0188	0.042	CbGeAlD
Dihydroxyaluminium—VDAC3—vagina—muscle cancer	0.0187	0.0417	CbGeAlD
Dihydroxyaluminium—VDAC1—bone marrow—muscle cancer	0.0185	0.0414	CbGeAlD
Dihydroxyaluminium—VDAC1—vagina—muscle cancer	0.0177	0.0397	CbGeAlD
Dihydroxyaluminium—VDAC3—head—muscle cancer	0.0172	0.0385	CbGeAlD
Dihydroxyaluminium—VDAC3—testis—muscle cancer	0.0166	0.0372	CbGeAlD
Dihydroxyaluminium—VDAC1—head—muscle cancer	0.0164	0.0366	CbGeAlD
Dihydroxyaluminium—TNNC1—tendon—muscle cancer	0.0164	0.0366	CbGeAlD
Dihydroxyaluminium—VDAC1—testis—muscle cancer	0.0158	0.0354	CbGeAlD
Dihydroxyaluminium—TNNC1—testis—muscle cancer	0.0136	0.0303	CbGeAlD
Dihydroxyaluminium—Blindness transient—Methotrexate—muscle cancer	0.0097	0.0721	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—IGF2—muscle cancer	0.00475	0.0114	CbGpPWpGaD
Dihydroxyaluminium—Extravasation—Dactinomycin—muscle cancer	0.00468	0.0348	CcSEcCtD
Dihydroxyaluminium—Extravasation—Vincristine—muscle cancer	0.00418	0.0311	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Dactinomycin—muscle cancer	0.00344	0.0256	CcSEcCtD
Dihydroxyaluminium—Extravasation—Etoposide—muscle cancer	0.00339	0.0252	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Etoposide—muscle cancer	0.00337	0.025	CcSEcCtD
Dihydroxyaluminium—Coma—Vincristine—muscle cancer	0.00334	0.0248	CcSEcCtD
Dihydroxyaluminium—Polyuria—Vincristine—muscle cancer	0.00302	0.0224	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Doxorubicin—muscle cancer	0.00284	0.0211	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Methotrexate—muscle cancer	0.00276	0.0205	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Vincristine—muscle cancer	0.00266	0.0198	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Vincristine—muscle cancer	0.00252	0.0187	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Methotrexate—muscle cancer	0.0025	0.0186	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Etoposide—muscle cancer	0.00249	0.0185	CcSEcCtD
Dihydroxyaluminium—Dehydration—Vincristine—muscle cancer	0.00246	0.0183	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Doxorubicin—muscle cancer	0.00217	0.0161	CcSEcCtD
Dihydroxyaluminium—Extravasation—Methotrexate—muscle cancer	0.00203	0.0151	CcSEcCtD
Dihydroxyaluminium—Chills—Dactinomycin—muscle cancer	0.00184	0.0137	CcSEcCtD
Dihydroxyaluminium—Extravasation—Doxorubicin—muscle cancer	0.00176	0.0131	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Doxorubicin—muscle cancer	0.00175	0.013	CcSEcCtD
Dihydroxyaluminium—Coma—Methotrexate—muscle cancer	0.00162	0.012	CcSEcCtD
Dihydroxyaluminium—Back pain—Vincristine—muscle cancer	0.00154	0.0115	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Doxorubicin—muscle cancer	0.00149	0.0111	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Methotrexate—muscle cancer	0.00149	0.011	CcSEcCtD
Dihydroxyaluminium—Polyuria—Methotrexate—muscle cancer	0.00146	0.0109	CcSEcCtD
Dihydroxyaluminium—Oedema—Dactinomycin—muscle cancer	0.00146	0.0108	CcSEcCtD
Dihydroxyaluminium—Infection—Dactinomycin—muscle cancer	0.00145	0.0108	CcSEcCtD
Dihydroxyaluminium—Vertigo—Vincristine—muscle cancer	0.00143	0.0107	CcSEcCtD
Dihydroxyaluminium—Coma—Doxorubicin—muscle cancer	0.0014	0.0104	CcSEcCtD
Dihydroxyaluminium—Convulsion—Vincristine—muscle cancer	0.00138	0.0103	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Methotrexate—muscle cancer	0.00136	0.0101	CcSEcCtD
Dihydroxyaluminium—Chills—Etoposide—muscle cancer	0.00133	0.00991	CcSEcCtD
Dihydroxyaluminium—Oedema—Vincristine—muscle cancer	0.0013	0.00968	CcSEcCtD
Dihydroxyaluminium—Infection—Vincristine—muscle cancer	0.00129	0.00962	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Doxorubicin—muscle cancer	0.00129	0.00961	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Doxorubicin—muscle cancer	0.00129	0.00956	CcSEcCtD
Dihydroxyaluminium—Back pain—Etoposide—muscle cancer	0.00125	0.0093	CcSEcCtD
Dihydroxyaluminium—Pain—Dactinomycin—muscle cancer	0.00125	0.00927	CcSEcCtD
Dihydroxyaluminium—Hypotension—Vincristine—muscle cancer	0.00122	0.00905	CcSEcCtD
Dihydroxyaluminium—Vertigo—Etoposide—muscle cancer	0.00116	0.00864	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Dactinomycin—muscle cancer	0.00115	0.00857	CcSEcCtD
Dihydroxyaluminium—Convulsion—Etoposide—muscle cancer	0.00112	0.00833	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Doxorubicin—muscle cancer	0.00112	0.00831	CcSEcCtD
Dihydroxyaluminium—Pain—Vincristine—muscle cancer	0.00111	0.00828	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Dactinomycin—muscle cancer	0.00107	0.00799	CcSEcCtD
Dihydroxyaluminium—Infection—Etoposide—muscle cancer	0.00105	0.00779	CcSEcCtD
Dihydroxyaluminium—Dehydration—Doxorubicin—muscle cancer	0.00104	0.0077	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Etoposide—muscle cancer	0.00103	0.00766	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Vincristine—muscle cancer	0.00103	0.00766	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Dactinomycin—muscle cancer	0.000997	0.00742	CcSEcCtD
Dihydroxyaluminium—Hypotension—Etoposide—muscle cancer	0.000986	0.00733	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Vincristine—muscle cancer	0.000959	0.00713	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Doxorubicin—muscle cancer	0.000937	0.00697	CcSEcCtD
Dihydroxyaluminium—Vomiting—Dactinomycin—muscle cancer	0.000927	0.00689	CcSEcCtD
Dihydroxyaluminium—Pain—Etoposide—muscle cancer	0.000902	0.00671	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Vincristine—muscle cancer	0.000891	0.00663	CcSEcCtD
Dihydroxyaluminium—Nausea—Dactinomycin—muscle cancer	0.000866	0.00644	CcSEcCtD
Dihydroxyaluminium—Dizziness—Vincristine—muscle cancer	0.000861	0.0064	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Methotrexate—muscle cancer	0.000857	0.00637	CcSEcCtD
Dihydroxyaluminium—Urticaria—Etoposide—muscle cancer	0.000838	0.00623	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Etoposide—muscle cancer	0.000834	0.0062	CcSEcCtD
Dihydroxyaluminium—Vomiting—Vincristine—muscle cancer	0.000828	0.00616	CcSEcCtD
Dihydroxyaluminium—Chills—Methotrexate—muscle cancer	0.000798	0.00593	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Etoposide—muscle cancer	0.000777	0.00578	CcSEcCtD
Dihydroxyaluminium—Nausea—Vincristine—muscle cancer	0.000774	0.00575	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Doxorubicin—muscle cancer	0.000772	0.00574	CcSEcCtD
Dihydroxyaluminium—Back pain—Methotrexate—muscle cancer	0.000749	0.00557	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Doxorubicin—muscle cancer	0.000742	0.00552	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Methotrexate—muscle cancer	0.00073	0.00543	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Etoposide—muscle cancer	0.000722	0.00537	CcSEcCtD
Dihydroxyaluminium—Dizziness—Etoposide—muscle cancer	0.000698	0.00519	CcSEcCtD
Dihydroxyaluminium—Vertigo—Methotrexate—muscle cancer	0.000696	0.00517	CcSEcCtD
Dihydroxyaluminium—Chills—Doxorubicin—muscle cancer	0.000691	0.00514	CcSEcCtD
Dihydroxyaluminium—Convulsion—Methotrexate—muscle cancer	0.000671	0.00499	CcSEcCtD
Dihydroxyaluminium—Vomiting—Etoposide—muscle cancer	0.000671	0.00499	CcSEcCtD
Dihydroxyaluminium—Back pain—Doxorubicin—muscle cancer	0.000648	0.00482	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Doxorubicin—muscle cancer	0.000632	0.0047	CcSEcCtD
Dihydroxyaluminium—Infection—Methotrexate—muscle cancer	0.000628	0.00467	CcSEcCtD
Dihydroxyaluminium—Nausea—Etoposide—muscle cancer	0.000627	0.00466	CcSEcCtD
Dihydroxyaluminium—Vertigo—Doxorubicin—muscle cancer	0.000602	0.00448	CcSEcCtD
Dihydroxyaluminium—Hypotension—Methotrexate—muscle cancer	0.00059	0.00439	CcSEcCtD
Dihydroxyaluminium—Convulsion—Doxorubicin—muscle cancer	0.000581	0.00432	CcSEcCtD
Dihydroxyaluminium—Oedema—Doxorubicin—muscle cancer	0.000547	0.00407	CcSEcCtD
Dihydroxyaluminium—Infection—Doxorubicin—muscle cancer	0.000544	0.00404	CcSEcCtD
Dihydroxyaluminium—Pain—Methotrexate—muscle cancer	0.00054	0.00402	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Doxorubicin—muscle cancer	0.000534	0.00397	CcSEcCtD
Dihydroxyaluminium—Hypotension—Doxorubicin—muscle cancer	0.000511	0.0038	CcSEcCtD
Dihydroxyaluminium—Urticaria—Methotrexate—muscle cancer	0.000502	0.00373	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Methotrexate—muscle cancer	0.0005	0.00371	CcSEcCtD
Dihydroxyaluminium—Pain—Doxorubicin—muscle cancer	0.000468	0.00348	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Methotrexate—muscle cancer	0.000466	0.00346	CcSEcCtD
Dihydroxyaluminium—Urticaria—Doxorubicin—muscle cancer	0.000435	0.00323	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Doxorubicin—muscle cancer	0.000433	0.00322	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Methotrexate—muscle cancer	0.000432	0.00322	CcSEcCtD
Dihydroxyaluminium—Dizziness—Methotrexate—muscle cancer	0.000418	0.00311	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Doxorubicin—muscle cancer	0.000403	0.003	CcSEcCtD
Dihydroxyaluminium—Vomiting—Methotrexate—muscle cancer	0.000402	0.00299	CcSEcCtD
Dihydroxyaluminium—Nausea—Methotrexate—muscle cancer	0.000375	0.00279	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Doxorubicin—muscle cancer	0.000374	0.00278	CcSEcCtD
Dihydroxyaluminium—Dizziness—Doxorubicin—muscle cancer	0.000362	0.00269	CcSEcCtD
Dihydroxyaluminium—Vomiting—Doxorubicin—muscle cancer	0.000348	0.00259	CcSEcCtD
Dihydroxyaluminium—Nausea—Doxorubicin—muscle cancer	0.000325	0.00242	CcSEcCtD
